Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Curcumin as tyrosine kinase inhibitor in cancer treatment.

Golonko A, Lewandowska H, Świsłocka R, Jasińska UT, Priebe W, Lewandowski W.

Eur J Med Chem. 2019 Nov 1;181:111512. doi: 10.1016/j.ejmech.2019.07.015. Epub 2019 Jul 15. Review.

PMID:
31404861
2.

Hyperpolarized Pyruvate MR Spectroscopy Depicts Glycolytic Inhibition in a Mouse Model of Glioma.

Michel KA, Zieliński R, Walker CM, Le Roux L, Priebe W, Bankson JA, Schellingerhout D.

Radiology. 2019 Oct;293(1):168-173. doi: 10.1148/radiol.2019182919. Epub 2019 Aug 6.

3.

Profiles of brain metastases: Prioritization of therapeutic targets.

Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB.

Int J Cancer. 2018 Dec 1;143(11):3019-3026. doi: 10.1002/ijc.31624. Epub 2018 Oct 9.

4.

Maximizing Local Access to Therapeutic Deliveries in Glioblastoma. Part I: Targeted Cytotoxic Therapy.

Debinski W, Priebe W, Tatter SB.

In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 17.

5.

Novel Molecular Multilevel Targeted Antitumor Agents.

Sonawane P, Choi YA, Pandya H, Herpai DM, Fokt I, Priebe W, Debinski W.

Cancer Transl Med. 2017 May-Jun;3(3):69-79. doi: 10.4103/ctm.ctm_12_17. Epub 2017 Jun 8.

6.

Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation.

Olbryt M, Rusin A, Fokt I, Habryka A, Tudrej P, Student S, Sochanik A, Zieliński R, Priebe W.

Invest New Drugs. 2017 Oct;35(5):545-555. doi: 10.1007/s10637-017-0465-9. Epub 2017 Apr 17.

7.

Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma.

Santoro M, Menegaz BA, Lamhamedi-Cherradi SE, Molina ER, Wu D, Priebe W, Ludwig JA, Mikos AG.

Tissue Eng Part A. 2017 Jan;23(1-2):80-89. doi: 10.1089/ten.TEA.2016.0369.

8.

IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.

Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA.

J Natl Cancer Inst. 2016 Aug 30;108(12). pii: djw182. doi: 10.1093/jnci/djw182. Print 2016 Dec.

9.

Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.

Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J, Bögler O.

J Transl Med. 2016 Feb 9;14:46. doi: 10.1186/s12967-016-0803-2.

10.

Obituary: Derek Horton (1933-2015).

Priebe W.

Glycoconj J. 2015 Nov;32(8):557-8. doi: 10.1007/s10719-015-9617-3. No abstract available.

PMID:
26498188
11.

Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway.

Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang FF.

Stem Cells. 2015 Aug;33(8):2400-15. doi: 10.1002/stem.2053. Epub 2015 May 27.

12.

Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells.

Lee HT, Xue J, Chou PC, Zhou A, Yang P, Conrad CA, Aldape KD, Priebe W, Patterson C, Sawaya R, Xie K, Huang S.

Oncotarget. 2015 Apr 30;6(12):10016-29.

13.

Autophagy modulates the effects of bis-anthracycline WP631 on p53-deficient prostate cancer cells.

Mansilla S, Vizcaíno C, Rodríguez-Sánchez MA, Priebe W, Portugal J.

J Cell Mol Med. 2015 Apr;19(4):786-98. doi: 10.1111/jcmm.12402. Epub 2015 Feb 16.

14.

Therapeutic targets in subependymoma.

Kong LY, Wei J, Haider AS, Liebelt BD, Ling X, Conrad CA, Fuller GN, Levine NB, Priebe W, Sawaya R, Heimberger AB.

J Neuroimmunol. 2014 Dec 15;277(1-2):168-75. doi: 10.1016/j.jneuroim.2014.10.008. Epub 2014 Oct 31.

PMID:
25465288
15.

Apples: content of phenolic compounds vs. variety, part of apple and cultivation model, extraction of phenolic compounds, biological properties.

Kalinowska M, Bielawska A, Lewandowska-Siwkiewicz H, Priebe W, Lewandowski W.

Plant Physiol Biochem. 2014 Nov;84:169-188. doi: 10.1016/j.plaphy.2014.09.006. Epub 2014 Sep 16.

PMID:
25282014
16.

Analogs of cinnamic acid benzyl amide as nonclassical inhibitors of activated JAK2 kinase.

Mielecki M, Milner-Krawczyk M, Grzelak K, Mielecki D, Krzysko KA, Lesyng B, Priebe W.

Curr Cancer Drug Targets. 2014;14(7):638-51.

PMID:
25146330
17.

Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo.

Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W, Giraud AS.

PLoS One. 2014 May 7;9(5):e95993. doi: 10.1371/journal.pone.0095993. eCollection 2014.

18.

Integrative biological analysis for neuropsychopharmacology.

Emmett MR, Kroes RA, Moskal JR, Conrad CA, Priebe W, Laezza F, Meyer-Baese A, Nilsson CL.

Neuropsychopharmacology. 2014 Jan;39(1):5-23. doi: 10.1038/npp.2013.156. Epub 2013 Jun 26. Review.

19.

Development of novel molecular probes of the Rio1 atypical protein kinase.

Mielecki M, Krawiec K, Kiburu I, Grzelak K, Zagórski W, Kierdaszuk B, Kowa K, Fokt I, Szymanski S, Swierk P, Szeja W, Priebe W, Lesyng B, LaRonde-LeBlanc N.

Biochim Biophys Acta. 2013 Jul;1834(7):1292-301. doi: 10.1016/j.bbapap.2013.03.012. Epub 2013 Mar 20.

PMID:
23523885
20.

D-Glucose and D-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated D-glucose, D-mannose, and 2-deoxy-D-glucose.

Fokt I, Skora S, Conrad C, Madden T, Emmett M, Priebe W.

Carbohydr Res. 2013 Mar 7;368:111-9. doi: 10.1016/j.carres.2012.11.021. Epub 2012 Dec 13.

21.

Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.

Garnett J, Chumbalkar V, Vaillant B, Gururaj AE, Hill KS, Latha K, Yao J, Priebe W, Colman H, Elferink LA, Bogler O.

Neoplasia. 2013 Jan;15(1):73-84.

22.

Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma.

Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bögler O, Heimberger AB, Rao G.

Neuro Oncol. 2012 Sep;14(9):1136-45. doi: 10.1093/neuonc/nos139. Epub 2012 Jun 29.

23.

Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells.

Swiatek-Machado K, Mieczkowski J, Ellert-Miklaszewska A, Swierk P, Fokt I, Szymanski S, Skora S, Szeja W, Grynkiewicz G, Lesyng B, Priebe W, Kaminska B.

Cancer Biol Ther. 2012 Jun;13(8):657-70. doi: 10.4161/cbt.20083. Epub 2012 Jun 1.

PMID:
22555804
24.

Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway.

Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H.

J Neurooncol. 2012 May;107(3):487-501. doi: 10.1007/s11060-011-0786-z. Epub 2012 Jan 17.

PMID:
22249692
25.

Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms.

Yan H, Chen X, Zhang Q, Qin J, Li H, Liu C, Calhoun-Davis T, Coletta LD, Klostergaard J, Fokt I, Skora S, Priebe W, Bi Y, Tang DG.

PLoS One. 2011;6(9):e24397. doi: 10.1371/journal.pone.0024397. Epub 2011 Sep 15.

26.

An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.

Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ.

Cancer Cell. 2011 Sep 13;20(3):384-99. doi: 10.1016/j.ccr.2011.08.013.

27.

A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination.

Kapuria V, Levitzki A, Bornmann WG, Maxwell D, Priebe W, Sorenson RJ, Showalter HD, Talpaz M, Donato NJ.

Cell Signal. 2011 Dec;23(12):2076-85. doi: 10.1016/j.cellsig.2011.08.002. Epub 2011 Aug 9.

PMID:
21855629
28.

The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.

Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB.

Int J Cancer. 2012 Jul 1;131(1):8-17. doi: 10.1002/ijc.26307. Epub 2011 Aug 24.

29.

Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.

Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, Davis-Malesevich M, Priebe W, Myers JN.

Cancer. 2011 Jul 1;117(13):2926-38. doi: 10.1002/cncr.25868. Epub 2011 Jan 10.

30.

Changes in gene expression induced by Sp1 knockdown differ from those caused by challenging Sp1 binding to gene promoters.

Mansilla S, Priebe W, Portugal J.

Biochim Biophys Acta. 2011 Jul;1809(7):327-36. doi: 10.1016/j.bbagrm.2011.06.003. Epub 2011 Jun 13.

PMID:
21684359
31.

A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer.

Ahmed AA, Goldsmith J, Fokt I, Le XF, Krzysko KA, Lesyng B, Bast RC Jr, Priebe W.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1033-44. doi: 10.1007/s00280-011-1575-2. Epub 2011 Feb 22.

32.

Hypoxia potentiates glioma-mediated immunosuppression.

Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W, Heimberger AB.

PLoS One. 2011 Jan 20;6(1):e16195. doi: 10.1371/journal.pone.0016195.

33.

Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.

Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R, Priebe W, Arlinghaus R.

Leukemia. 2011 Mar;25(3):463-72. doi: 10.1038/leu.2010.287. Epub 2010 Dec 24.

34.

Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.

Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN, Qiao W, Sawaya R, Rao G, Heimberger AB.

Clin Cancer Res. 2010 Dec 1;16(23):5722-33. doi: 10.1158/1078-0432.CCR-10-1693. Epub 2010 Oct 4.

35.

Glioma cancer stem cells induce immunosuppressive macrophages/microglia.

Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger AB.

Neuro Oncol. 2010 Nov;12(11):1113-25. doi: 10.1093/neuonc/noq082. Epub 2010 Jul 28.

36.

Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.

Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ.

Mol Cancer Ther. 2010 Jul;9(7):2026-36. doi: 10.1158/1535-7163.MCT-10-0238. Epub 2010 Jul 6.

37.

Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model.

Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB.

Clin Cancer Res. 2010 May 1;16(9):2550-61. doi: 10.1158/1078-0432.CCR-10-0279. Epub 2010 Apr 13.

38.

Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation.

He H, Nilsson CL, Emmett MR, Marshall AG, Kroes RA, Moskal JR, Ji Y, Colman H, Priebe W, Lang FF, Conrad CA.

J Proteome Res. 2010 May 7;9(5):2098-108. doi: 10.1021/pr900793a.

PMID:
20199106
39.

Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway.

Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB.

Mol Cancer Ther. 2010 Jan;9(1):67-78. doi: 10.1158/1535-7163.MCT-09-0734. Epub 2010 Jan 6.

40.

Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells.

Nilsson CL, Dillon R, Devakumar A, Shi SD, Greig M, Rogers JC, Krastins B, Rosenblatt M, Kilmer G, Major M, Kaboord BJ, Sarracino D, Rezai T, Prakash A, Lopez M, Ji Y, Priebe W, Lang FF, Colman H, Conrad CA.

J Proteome Res. 2010 Jan;9(1):430-43. doi: 10.1021/pr9007927.

PMID:
19899826
41.

D-glucose- and D-mannose-based antimetabolites. Part 2. Facile synthesis of 2-deoxy-2-halo-D-glucoses and -D-mannoses.

Fokt I, Szymanski S, Skora S, Cybulski M, Madden T, Priebe W.

Carbohydr Res. 2009 Aug 17;344(12):1464-73. doi: 10.1016/j.carres.2009.06.016. Epub 2009 Jun 21.

PMID:
19625015
43.

The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.

Heimberger AB, Kong LY, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Wei J, Qiao W, Schmittling RJ, Archer GE, Sampson JH, Hiraoka N, Priebe W, Fuller GN, Sawaya R.

Clin Neurosurg. 2009;56:98-106. Review. No abstract available.

PMID:
20214040
44.

Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma.

Kupferman ME, Jayakumar A, Zhou G, Xie T, Dakak-Yazici Y, Zhao M, Ju J, Mandal M, Jasser S, Madden T, Myers JN, Priebe W.

J Exp Ther Oncol. 2009;8(2):117-27.

PMID:
20192118
45.

The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas.

Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB.

Clin Cancer Res. 2008 Dec 15;14(24):8228-35. doi: 10.1158/1078-0432.CCR-08-1329.

46.

DFT study on the selectivity of complexation of metal cations with a dioxadithia crown ether ligand.

Korchowiec J, Korchowiec B, Priebe W, Rogalska E.

J Phys Chem A. 2008 Dec 25;112(51):13633-40. doi: 10.1021/jp8066052.

PMID:
19055400
47.

A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.

Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB.

Cancer Immunol Immunother. 2009 Jul;58(7):1023-32. doi: 10.1007/s00262-008-0618-y. Epub 2008 Nov 11.

48.

Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers.

Heimberger AB, Priebe W.

Recent Pat CNS Drug Discov. 2008 Nov;3(3):179-88. Review.

PMID:
18991807
49.

A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.

Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE Jr, Sampson JH, Priebe W, Heimberger AB.

Clin Cancer Res. 2008 Sep 15;14(18):5759-68. doi: 10.1158/1078-0432.CCR-08-0377.

50.

The inhibitory effect of 2-halo derivatives of D-glucose on glycolysis and on the proliferation of the human malaria parasite Plasmodium falciparum.

van Schalkwyk DA, Priebe W, Saliba KJ.

J Pharmacol Exp Ther. 2008 Nov;327(2):511-7. doi: 10.1124/jpet.108.141929. Epub 2008 Aug 19.

PMID:
18713952

Supplemental Content

Loading ...
Support Center